STERIS plc Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 07, 2023 at 04:40 pm EST
Share
STERIS plc reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was USD 1,342.36 million compared to USD 1,200.52 million a year ago. Net income was USD 115.32 million compared to net loss of USD 315.29 million a year ago. Basic earnings per share from continuing operations was USD 1.17 compared to basic loss per share from continuing operations of USD 3.15 a year ago. Diluted earnings per share from continuing operations was USD 1.16 compared to diluted loss per share from continuing operations of USD 3.15 a year ago.
For the six months, revenue was USD 2,626.9 million compared to USD 2,357.01 million a year ago. Net income was USD 238.87 million compared to net loss of USD 204.02 million a year ago. Basic earnings per share from continuing operations was USD 2.42 compared to basic loss per share from continuing operations of USD 2.04 a year ago. Diluted earnings per share from continuing operations was USD 2.41 compared to diluted loss per share from continuing operations of USD 2.04 a year ago.
STERIS plc is one of the world's leading providers of infection control solutions and procedural services. Net sales break down by activity as follows:
- sales of infection control solutions (62.9%): including cleaning and sterilization chemicals, accessories for gastrointestinal procedures, washers, sterilizers and operating room equipment (including surgical tables, lighting and connectivity solutions). In addition, the group offers specialized healthcare services (sterilization services, instrument and endoscope repair and maintenance and customized process improvement consulting in acute care hospitals);
- development of applied sterilization solutions (22.1%): contract development of sterilization modalities and laboratory testing services for more than 50 sterilization and laboratory facilities worldwide;
- manufacturing of consumables and maintenance equipment (15%): dedicated to pharmaceutical manufacturers.
Net sales by source of income are divided into sales of services (53.5%), sales of consumables (23.4%) and sales of equipment (23.1%).
Net sales are distributed geographically as follows Ireland (2.3%), the United States (71.7%) and other (26%).